Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease
dc.contributor.author | Farlow, Martin R. | |
dc.contributor.author | Sadowsky, Carl H. | |
dc.contributor.author | Velting, Drew M. | |
dc.contributor.author | Meng, Xiangyi | |
dc.contributor.author | Islam, M. Zahur | |
dc.contributor.department | Neurology, School of Medicine | en_US |
dc.date.accessioned | 2019-08-27T15:42:58Z | |
dc.date.available | 2019-08-27T15:42:58Z | |
dc.date.issued | 2015-06 | |
dc.description.abstract | AIMS: To identify factors predicting improvement/stabilization on the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and investigate whether early treatment responses can predict long-term outcomes, during a trial of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease (AD). METHODS: Logistic regression was used to relate Week 24 ADCS-CGIC score to potential baseline predictors. Additional analyses based on receiver-operating characteristic curves were performed using Week 8/16 ADCS-CGIC scores to predict response (13.3 mg/24 h patch) at Week 24. ADCS-CGIC score of (1) 1-3 = "improvement," (2) 1-4 = "improvement or no change". RESULTS: "Treatment" (13.3 mg/24 h patch) and increased age were significant predictors of "improvement" (P = 0.01 and P = 0.003, respectively), and "treatment" (P = 0.001), increased age (P = 0.002), and prior AD treatment (P = 0.03) for "improvement or no change". At Week 8 and 16, ADCS-CGIC scores of 4 and 5 were optimal thresholds in predicting "improvement," and "improvement or no change," respectively, at Week 24. CONCLUSIONS: A significant therapeutic effect of high-dose rivastigmine patch on ADCS-CGIC response was observed. The 13.3 mg/24 h patch was identified as a predictor of "improvement" or "improvement or no change". Patients with minimal worsening/improvement/no change after treatment initiation may be more likely to respond following long-term therapy. | en_US |
dc.identifier.citation | Farlow, M. R., Sadowsky, C. H., Velting, D. M., Meng, X., & Islam, M. Z. (2015). Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease. CNS neuroscience & therapeutics, 21(6), 513–519. doi:10.1111/cns.12385 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/20606 | |
dc.language.iso | en_US | en_US |
dc.publisher | Wiley | en_US |
dc.relation.isversionof | 10.1111/cns.12385 | en_US |
dc.relation.journal | CNS Neuroscience & Therapeutics | en_US |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/us | * |
dc.source | PMC | en_US |
dc.subject | Alzheimer disease | en_US |
dc.subject | Predictor | en_US |
dc.subject | Rivastigmine | en_US |
dc.subject | Receiver‐operating characteristic | en_US |
dc.subject | Transdermal patch | en_US |
dc.title | Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease | en_US |
dc.type | Article | en_US |